Harbour BioMed inks $350 million deal for rights to A167
Member News
USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167
Related or similar articles
April 14, 2019
Global 3D Printed Drugs Market Insights 2019-2024 : Extend Biosciences, Bioduro, Affinity Therapeutics
One of the dominating players in the 3D Printed Drugs market is Extend Biosciences
Member News
August 8, 2018
Harbour BioMed inks $350 million deal for rights to A167
USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167
Member News
December 10, 2021
Labshares Newton Doubles Space for Emerging Biotech Startups
NEWTON, Mass.--(BUSINESS WIRE)--Labshares Newton celebrated today the opening of 19,000 square feet of new incubator lab space and expects to open another 6,000-foot lab in September. Labshares’ new space incorporates 12 private suites, 15 lab ...
Labshares News